Mariane Bertagnolli

Dr. Mariane Bertagnolli

Laboratory of Maternal and Child Health, CIUSSS Nord-de l’Île-de-Montréal, School of Physical and Occupational Therapy, Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
HJHamdi A. Jama
Hamdi A. Jama
RMRikeish R. Muralitharan
Rikeish R. Muralitharan
CXChudan Xu
Chudan Xu
JOJoanne A. O'Donnell
Joanne A. O'Donnell
MBMariane Bertagnolli
Mariane Bertagnolli
FMFrancine Z. Marques
Francine Z. Marques

1 January 2014 in Peptides
Verified
Journal Article
Closed access
MBMariane Bertagnolli
Mariane Bertagnolli
KCKarina Rabello Casali
Karina Rabello Casali
FSFrederico De Sousa
Frederico De Sousa
KRKatya Rigatto
Katya Rigatto
LBLenice Becker
Lenice Becker
Robson SantosRobson Santos
Robson Santos

2 August 2021 in Clinical Science
Verified
Journal Article
Open access
PDF file
NCNayara Azinheira Nobrega Cruz
Nayara Azinheira Nobrega Cruz
DSDanielle Stoll
Danielle Stoll
DCDulce Elena Casarini
Dulce Elena Casarini
MBMariane Bertagnolli
Mariane Bertagnolli
In times of coronavirus disease 2019 (COVID-19), the impact of severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 infection on pregnancy is still unclear. The presence of angiotensin-converting enzyme (ACE) 2 (ACE2), the main receptor for SARS-CoV-2, in human placentas indicates that this organ can be vulnerable for viral infection during pregnancy. However, for this to happen, additional molecular processes are critical to allow viral entry in cells, its replication and disease manifestation, particularly in the placenta and/or feto–maternal circulation. Beyond the risk of vertical transmission, COVID-19 is also proposed to deplete ACE2 protein and its biological actions in the placenta. It is postulated that such effects may impair essential processes during placentation and maternal hemodynamic adaptations in COVID-19 pregnancy, features also observed in several disorders of pregnancy. This review gathers information indicating risks and protective features related to ACE2 changes in COVID-19 pregnancies. First, we describe the mechanisms of SARS-CoV-2 infection having ACE2 as a main entry door and current evidence of viral infection in the placenta. Further, we discuss the central role of ACE2 in physiological systems such as the renin–angiotensin system (RAS) and the kallikrein–kinin system (KKS), both active during placentation and hemodynamic adaptations of pregnancy. Significant knowledge gaps are also identified and should be urgently filled to better understand the fate of ACE2 in COVID-19 pregnancies and the potential associated risks. Emerging knowledge will be able to improve the early stratification of high-risk pregnancies with COVID-19 exposure as well as to guide better management and follow-up of these mothers and their children.

13 May 2022 in eClinicalMedicine
Verified
Journal Article
Open access
WWWilby Williamson
Wilby Williamson
ALAdam Lewandowski
Adam Lewandowski
OHOdaro John Huckstep
Odaro John Huckstep
Winok LapidaireWinok Lapidaire
Winok Lapidaire
AOAlexander Ooms
Alexander Ooms
PLPaul Leeson
Paul Leeson
Exercise is advised for young adults with elevated blood pressure, but no trials have investigated efficacy at this age. We aimed to determine whether aerobic exercise, self-monitoring and motivational coaching lowers blood pressure in this group. The study was a single-centre, open, two-arm, parallel superiority randomized clinical trial with open community-based recruitment of physically-inactive 18–35 year old adults with awake 24 h blood pressure 115/75mmHg-159/99 mmHg and BMI<35 kg/m2. The study took place in the Cardiovascular Clinical Research Facility, John Radcliffe Hospital, Oxford, UK. Participants were randomized (1:1) with minimisation factors sex, age (<24, 24–29, 30–35 years) and gestational age at birth (37 weeks) to the intervention group, who received 16-weeks aerobic exercise training (three aerobic training sessions per week of 60 min per session at 60–80% peak heart rate, physical activity self-monitoring with encouragement to do 10,000 steps per day and motivational coaching to maintain physical activity upon completion of the intervention. The control group were sign-posted to educational materials on hypertension and recommended lifestyle behaviours. Investigators performing statistical analyses were blinded to group allocation. The primary outcome was 24 h awake ambulatory blood pressure (systolic and diastolic) change from baseline to 16-weeks on an intention-to-treat basis. Clinicaltrials.gov registered on March 30, 2016 (NCT02723552). Enrolment occurred between 30/06/2016-26/10/2018. Amongst the 203 randomized young adults (n = 102 in the intervention group; n = 101 in the control group), 178 (88%; n = 76 intervention group, n = 84 control group) completed 16-week follow-up and 160 (79%; n = 68 intervention group, n = 69 control group) completed 52-weeks follow-up. There were no group differences in awake systolic (0·0 mmHg [95%CI, -2·9 to 2·8]; P = 0·98) or awake diastolic ambulatory blood pressure (0·6 mmHg [95%CI, -1·4. to 2·6]; P = 0·58). Aerobic training increased peak oxygen uptake (2·8 ml/kg/min [95%CI, 1·6 to 4·0]) and peak wattage (14·2watts [95%CI, 7·6 to 20·9]) at 16-weeks. There were no intervention effects at 52-weeks follow-up. These results do not support the exclusive use of moderate to high intensity aerobic exercise training for blood pressure control in young adults. Wellcome Trust, British Heart Foundation, National Institute for Health Research, Oxford Biomedical Research Centre.

1 May 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
HBHolger Burchert
Holger Burchert
Winok LapidaireWinok Lapidaire
Winok Lapidaire
WWWilby Williamson
Wilby Williamson
AMAnnabelle McCourt
Annabelle McCourt
CDCameron Dockerill
Cameron Dockerill
ALAdam Lewandowski
Adam Lewandowski
Rationale: Premature birth is an independent predictor of long-term cardiovascular risk. Individuals affected are reported to have a lower rate of V˙ o 2 at peak exercise intensity (V˙ o 2PEAK) and at the ventilatory anaerobic threshold (V˙ o 2VAT), but little is known about their response to exercise training. Objectives: The primary objective was to determine whether the V˙ o 2PEAK response to exercise training differed between preterm-born and term-born individuals; the secondary objective was to quantify group differences in V˙ o 2VAT response. Methods: Fifty-two preterm-born and 151 term-born participants were randomly assigned (1:1) to 16 weeks of aerobic exercise training (n = 102) or a control group (n = 101). Cardiopulmonary exercise tests were conducted before and after the intervention to measure V˙ o 2PEAK and the V˙ o 2VAT. A prespecified subgroup analysis was conducted by fitting an interaction term for preterm and term birth histories and exercise group allocation. Measurements and Main Results: For term-born participants, V˙ o 2PEAK increased by 3.1 ml/kg/min (95% confidence interval [CI], 1.7 to 4.4), and the V˙ o 2VAT increased by 2.3 ml/kg/min (95% CI, 0.7 to 3.8) in the intervention group versus controls. For preterm-born participants, V˙ o 2PEAK increased by 1.8 ml/kg/min (95% CI, −0.4 to 3.9), and the V˙ o 2VAT increased by 4.6 ml/kg/min (95% CI, 2.1 to 7.0) in the intervention group versus controls. No significant interaction was observed with birth history for V˙ o 2PEAK (P = 0.32) or the V˙ o 2VAT (P = 0.12). Conclusions: The training intervention led to significant improvements in V˙ o 2PEAK and V˙ o 2VAT, with no evidence of a statistically different response based on birth history. Clinical trial registered with www.clinicaltrials.gov (NCT02723552).

19 September 2024 in Canadian Journal of Cardiology
Verified
Journal Article
Open access
CNCecilia Nieves
Cecilia Nieves
PGPaola Victoria da Costa Ghignatti
Paola Victoria da Costa Ghignatti
NANarjiss Aji
Narjiss Aji
MBMariane Bertagnolli
Mariane Bertagnolli
Pre-eclampsia is a severe pregnancy disorder affecting approximately 10% of pregnancies worldwide, characterized by hypertension and proteinuria after the 20th week of gestation. The condition poses significant risks to both maternal and fetal health, including cardiovascular complications and impaired fetal development. Recent trends indicate a rising incidence of pre-eclampsia, correlating with factors such as advanced maternal age and cardiovascular comorbidities. Emerging evidence also highlights a notable increase in the association between autoimmune and infectious diseases with pre-eclampsia. Autoimmune conditions, such as type 1 diabetes and systemic lupus erythematosus, and infections triggered by global health challenges and climate change, including Leptospirosis, Zika, Toxoplasmosis, and Chagas' disease, are now recognized as significant contributors to pre-eclampsia susceptibility by affecting placental formation and function. This review focuses on the immunological mechanisms underpinning pre-eclampsia, exploring how immune system dysregulation and infectious triggers exacerbate the condition. It also discusses the shared pathological mechanisms, including galectins, between autoimmune and infectious diseases with pre-eclampsia and their significant risk for adverse pregnancy outcomes. We emphasize the necessity for accurate diagnosis and vigilant monitoring of immune and infectious diseases during pregnancy to optimize management and reduce risks. By raising awareness about these evolving risks and their impact on pregnancy, we aim to enhance diagnostic practices and preventive strategies, ultimately improving outcomes for pregnant women, especially in regions affected by climatic changes and endemic diseases.